|
Name |
Vermixocin A
|
Molecular Formula | C21H24O6 | |
IUPAC Name* |
6-hydroxy-2-(1-hydroxy-3-methylbutyl)-1-methoxy-8-methyl-10H-benzo[b][1,5]benzodioxocin-12-one
|
|
SMILES |
CC1=CC2=C(C(=C1)O)OC3=C(C(=C(C=C3)C(CC(C)C)O)OC)C(=O)OC2
|
|
InChI |
InChI=1S/C21H24O6/c1-11(2)7-15(22)14-5-6-17-18(20(14)25-4)21(24)26-10-13-8-12(3)9-16(23)19(13)27-17/h5-6,8-9,11,15,22-23H,7,10H2,1-4H3
|
|
InChIKey |
UOWGLBYIKHMCIS-UHFFFAOYSA-N
|
|
Synonyms |
Vermixocin A; 55303-92-9; 6-Hydroxy-2-(1-hydroxy-3-methylbutyl)-1-methoxy-8-methyl-10H-benzo[b][1,5]benzodioxocin-12-one; MLS000876835; MEGxm0_000100; CHEMBL1482850; ACon0_000965; ACon1_001043; HMS2271J09; NCGC00169730-03; SMR000440585; L008625; BRD-A46837972-001-01-0; 156966-02-8; NCGC00169730-03_C21H24O6_5H,7H-Dibenzo[b,g][1,5]dioxocin-5-one, 11-hydroxy-3-(1-hydroxy-3-methylbutyl)-4-methoxy-9-methyl-
|
|
CAS | 156966-02-8 | |
PubChem CID | 9842429 | |
ChEMBL ID | CHEMBL1482850 |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 372.4 | ALogp: | 3.7 |
HBD: | 2 | HBA: | 6 |
Rotatable Bonds: | 4 | Lipinski's rule of five: | Accepted |
Polar Surface Area: | 85.2 | Aromatic Rings: | 3 |
Heavy Atoms: | 27 | QED Weighted: | 0.749 |
Caco-2 Permeability: | -4.97 | MDCK Permeability: | 0.00002050 |
Pgp-inhibitor: | 0.014 | Pgp-substrate: | 0.011 |
Human Intestinal Absorption (HIA): | 0.036 | 20% Bioavailability (F20%): | 0.006 |
30% Bioavailability (F30%): | 0.002 |
Blood-Brain-Barrier Penetration (BBB): | 0.156 | Plasma Protein Binding (PPB): | 97.48% |
Volume Distribution (VD): | 0.566 | Fu: | 3.27% |
CYP1A2-inhibitor: | 0.85 | CYP1A2-substrate: | 0.849 |
CYP2C19-inhibitor: | 0.888 | CYP2C19-substrate: | 0.526 |
CYP2C9-inhibitor: | 0.747 | CYP2C9-substrate: | 0.877 |
CYP2D6-inhibitor: | 0.543 | CYP2D6-substrate: | 0.562 |
CYP3A4-inhibitor: | 0.424 | CYP3A4-substrate: | 0.468 |
Clearance (CL): | 11.895 | Half-life (T1/2): | 0.494 |
hERG Blockers: | 0.027 | Human Hepatotoxicity (H-HT): | 0.016 |
Drug-inuced Liver Injury (DILI): | 0.178 | AMES Toxicity: | 0.331 |
Rat Oral Acute Toxicity: | 0.708 | Maximum Recommended Daily Dose: | 0.931 |
Skin Sensitization: | 0.791 | Carcinogencity: | 0.857 |
Eye Corrosion: | 0.003 | Eye Irritation: | 0.705 |
Respiratory Toxicity: | 0.521 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC000877 | 1.000 | D04UTT | 0.310 | ||||
ENC004018 | 0.805 | D0L1JW | 0.294 | ||||
ENC002005 | 0.773 | D06GCK | 0.288 | ||||
ENC002739 | 0.724 | D06GIP | 0.288 | ||||
ENC002740 | 0.724 | D07MGA | 0.286 | ||||
ENC006148 | 0.724 | D04TDQ | 0.282 | ||||
ENC004016 | 0.721 | D02FCQ | 0.277 | ||||
ENC004017 | 0.682 | D0Z1WA | 0.272 | ||||
ENC006147 | 0.644 | D03DJL | 0.268 | ||||
ENC003674 | 0.625 | D02LZB | 0.263 |